Abstract
Squamous cell carcinoma of the esophagus is one of the ten most frequent malignancies worldwide, characterized by a striking geographic variation in incidence. In North America and Europe, there has recently been a marked change in the epidemiology of this disease, where incidence rates for primary esophageal adenocarcinoma have increased in excess of any other human solid tumor. Although the reasons for this are largely unknown, several molecular genetic alterations have been associated with esophageal tumor progression. In recent years, epigenetic aberrations have been increasingly recognized as an important alternative mechanism of carcinogenesis and it is anticipated that substantial progress in the treatment of esophageal malignancy will likely only be made with a clearer understanding of esophageal tumor biology. Whereas genetic mutations, deletions, or allelic losses are fixed and irreversible, epigenetic abnormalities can potentially be corrected without interfering with the fundamental sequence of the target gene. Our current understanding of epigenetics in esophageal cancer, and the potential for targeted epigenetic therapy, will be the subject of this review.
Keywords: Epigenetics, DNA methylation, Histone modification, Genomic imprinting, Therapeutic targets, Esophageal cancer, Barrett esophagus
Current Cancer Drug Targets
Title: Epigenetic Aberrations and Targeted Epigenetic Therapy of Esophageal Cancer
Volume: 8 Issue: 6
Author(s): Ronghua Zhao and Alan G. Casson
Affiliation:
Keywords: Epigenetics, DNA methylation, Histone modification, Genomic imprinting, Therapeutic targets, Esophageal cancer, Barrett esophagus
Abstract: Squamous cell carcinoma of the esophagus is one of the ten most frequent malignancies worldwide, characterized by a striking geographic variation in incidence. In North America and Europe, there has recently been a marked change in the epidemiology of this disease, where incidence rates for primary esophageal adenocarcinoma have increased in excess of any other human solid tumor. Although the reasons for this are largely unknown, several molecular genetic alterations have been associated with esophageal tumor progression. In recent years, epigenetic aberrations have been increasingly recognized as an important alternative mechanism of carcinogenesis and it is anticipated that substantial progress in the treatment of esophageal malignancy will likely only be made with a clearer understanding of esophageal tumor biology. Whereas genetic mutations, deletions, or allelic losses are fixed and irreversible, epigenetic abnormalities can potentially be corrected without interfering with the fundamental sequence of the target gene. Our current understanding of epigenetics in esophageal cancer, and the potential for targeted epigenetic therapy, will be the subject of this review.
Export Options
About this article
Cite this article as:
Zhao Ronghua and Casson G. Alan, Epigenetic Aberrations and Targeted Epigenetic Therapy of Esophageal Cancer, Current Cancer Drug Targets 2008; 8 (6) . https://dx.doi.org/10.2174/156800908785699306
DOI https://dx.doi.org/10.2174/156800908785699306 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Multi-targeted Natural Flavonoid Myricetin Suppresses Lamellipodia and Focal Adhesions Formation and Impedes Glioblastoma Cell Invasiveness and Abnormal Motility
CNS & Neurological Disorders - Drug Targets Protection and Restitution of Gut Barrier by Probiotics: Nutritional and Clinical Implications
Current Nutrition & Food Science Approaching the Increasing Complexity of Non-small Cell Lung Cancer Taxonomy
Current Pharmaceutical Design Choline Nutrition Programs Brain Development Via DNA and Histone Methylation
Central Nervous System Agents in Medicinal Chemistry Cytokines and Hormones in the Regulation of Hypoxia Inducible Factor-1α (HIF-1α)
Cardiovascular & Hematological Agents in Medicinal Chemistry Detection and Specific Targeting of Hypoxic Regions within Solid Tumors: Current Preclinical and Clinical Strategies
Current Medicinal Chemistry Choosing Optimal Firstline Helicobacter pylori Therapy: a View from a Region with High Rates of Antibiotic Resistance
Current Pharmaceutical Design Overview of the Role of Macrophage Migration Inhibitory Factor (MIF) in Inflammatory Bowel Disease
Current Pharmaceutical Design Reversing Aberrant Methylation Patterns in Cancer
Current Medicinal Chemistry Base Excision Repair: Contribution to Tumorigenesis and Target in Anticancer Treatment Paradigms
Current Medicinal Chemistry Evaluating the Susceptibility of Mitochondrial DNA Germline Mutations in Chinese Cancer Patients
Current Molecular Medicine The Epidemiological, Mechanistic and Potential Clinical Role of Androgen Receptor (AR) in Urothelial Carcinoma
Current Drug Targets Recent Findings on the Application of Toll-like Receptors Agonists in Cancer Therapy
Current Medicinal Chemistry Segmentation and Classification of Lung Cancer: A Review
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Genomic and Cellular Pathology of Lung Cancer
Current Respiratory Medicine Reviews Cytotoxic Effect of the Red Beetroot (Beta vulgaris L.) Extract Compared to Doxorubicin (Adriamycin) in the Human Prostate (PC-3) and Breast (MCF-7) Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Interstitial Lung Disease in Systemic Sclerosis: A Single-center Retrospective Analysis
Current Rheumatology Reviews Transcriptional Regulation of mPGES1 in Cancer: An Alternative Approach to Drug Discovery?
Current Drug Targets Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells
Current Medicinal Chemistry Tumor Invasion and Oxidative Stress: Biomarkers and Therapeutic Strategies
Current Molecular Medicine